Development of tridentate iron chelators: from desferrithiocin to ICL670.
about
Pharmacology of iron transportIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesSynthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenesTargeting iron metabolism in drug discovery and deliveryInhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.Hypersensitivity reaction with deferasirox.A Speciation Study on the Perturbing Effects of Iron Chelators on the Homeostasis of Essential Metal Ions.4-[3,5-Bis(2-hy-droxy-phen-yl)-1H-1,2,4-triazol-1-yl]benzoic acid dimethyl-formamide monosolvate.Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.Targeting iron assimilation to develop new antibacterials.Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.Deferasirox: appraisal of safety and efficacy in long-term therapy.Korean guideline for iron chelation therapy in transfusion-induced iron overload.Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.Desferrithiocin analogues and nephrotoxicity.Malaria and iron: history and review.Deferasirox: an update.Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.The impact of hematopoietic stem cell transplantation on the management of thalassemia.Design of clinically useful macromolecular iron chelators.Deferasirox: pharmacokinetics and clinical experience.Different approaches to the study of chelating agents for iron and aluminium overload pathologies.Iron chelation in the treatment of cancer: a new role for deferasirox?Clinical pharmacology of deferasirox.Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.Role of pharmacogenetics on deferasirox AUC and efficacy.Deferoxamine synergistically enhances iron-mediated AP-1 activation: a showcase of the interplay between extracellular-signal-regulated kinase and tyrosine phosphatase.New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia majorInfluence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Recent advances in β-thalassemiasUpdate on the use of deferasirox in the management of iron overload.Iron chelation therapy in thalassemia syndromesSafety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.Four-component synthesis of fully substituted 1,2,4-triazoles.Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.
P2860
Q27009387-6880E5B8-D8DA-4710-A7A3-8A189C3F91D4Q28388335-CD5160B1-DD7F-4ADA-8B51-457FFD55862CQ30615373-B2999C44-7E7E-43E6-AD67-B89310924599Q33757232-C3FC9E62-4BDD-4F8A-AC24-E438EBA999ECQ34019744-AC5F1325-42A3-4F38-A44C-5622F8109EB0Q35568191-74543F14-0D15-4E7C-9E16-4DB5B7C1CAE1Q35698528-3CF97930-0CAB-4AFA-9ADA-F4D1052A4959Q35816061-45C88F1C-7A25-4C79-8988-2A27C3CD02CAQ35919222-66501D78-22AA-4B02-9848-239A3B4E1797Q36211648-37A482A9-AC84-4577-9CF4-7F2610A0E421Q36518462-0AC06DB1-725B-419B-ACA1-8C5F4B9B90DBQ36946007-EF625E40-085E-4DFD-AA10-98D9B8D39E11Q37084711-5F19B9D4-FF19-4204-99EE-C8A40018E323Q37095523-68FA245E-5B97-407A-8506-B0DF7954016BQ37329555-804AEEEF-82CD-489C-AF4C-C0389452846EQ37343763-A3DC44DC-070C-47FB-AC76-990FFF96B186Q37423512-DF524B89-CE10-4B2B-B3C7-847A3436AB1CQ37599856-21494722-5D48-483A-878C-3919483797FCQ37650465-4E31040F-3BD9-4995-B575-A30BC5E244D1Q37762810-2681B56D-2315-45D5-BDB9-A683C4ACA06CQ37810097-4935A997-B90E-4339-84FD-4AD1828C2EFCQ37884088-9521B4DC-1DE2-4CD9-A1B2-FA61A5D52FAAQ37969225-F2705207-18D0-4839-BAFD-9B4E50543F8DQ38055398-F2C44333-2BBB-4A85-AC87-96D6DA31DF9DQ38112400-F733B913-1577-4E17-AE61-D39F322A45B4Q38226394-792EA474-078F-4106-9633-411F1EC41154Q38298216-829D500A-F0A3-449C-86CE-F458C3CDCCC2Q38874222-AB472020-DAA2-468D-AD9A-4F8754C2D5DDQ39269756-22E425BD-ACF6-4C34-8AFB-D4C002054010Q39865051-862DA2E1-55C5-437E-A7A8-B3C9FA858783Q40077717-7D0A4DC6-2F84-4708-B314-D04F8F36C8E1Q40098290-D201330E-01CB-4D67-8DCC-CDC38330C6BBQ40762243-9F362C8F-2177-4199-BE3A-AD28D069700BQ41687355-88056202-3AC9-4E1D-A3DE-3F99A5AD51AEQ41973193-83FA0BF5-3221-44A9-91A7-474FD13D0C9AQ42117340-D2B26344-C614-439E-95BE-E0B54640FD95Q42588949-2A86DF0C-066A-4361-B3A7-29F7C738CD2CQ43199274-991546BA-B765-4FB5-985D-8A54E0A03C66Q43226746-AB1AFFE1-74A9-4E40-ADBD-31B7C18EBA6DQ43235333-EE1D58C9-521D-46FD-8DBA-F6D1B2902282
P2860
Development of tridentate iron chelators: from desferrithiocin to ICL670.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Development of tridentate iron chelators: from desferrithiocin to ICL670.
@ast
Development of tridentate iron chelators: from desferrithiocin to ICL670.
@en
type
label
Development of tridentate iron chelators: from desferrithiocin to ICL670.
@ast
Development of tridentate iron chelators: from desferrithiocin to ICL670.
@en
prefLabel
Development of tridentate iron chelators: from desferrithiocin to ICL670.
@ast
Development of tridentate iron chelators: from desferrithiocin to ICL670.
@en
P2093
P356
P1476
Development of tridentate iron chelators: from desferrithiocin to ICL670.
@en
P2093
Daniele Alberti
Hanspeter Nick
Joachim Schupp
Peter Buehlmayer
Pierre Acklin
René Lattmann
Suzanne Hauffe
P304
P356
10.2174/0929867033457610
P577
2003-06-01T00:00:00Z